{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+dose+Placebo&page=19",
    "query": {
      "intervention": "High dose Placebo",
      "page": 19
    },
    "page_size": 10
  },
  "pagination": {
    "page": 19,
    "page_size": 10,
    "total_count": 2058,
    "total_pages": 206,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+dose+Placebo&page=20&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High+dose+Placebo&page=18&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-21T01:48:33.148Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02697292",
      "title": "IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Autoimmune Epilepsy"
      ],
      "interventions": [
        {
          "name": "Intravenous Immunoglobulin",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 17,
      "start_date": "2016-02",
      "completion_date": "2018-12-03",
      "has_results": true,
      "last_update_posted_date": "2019-12-30",
      "last_synced_at": "2026-11-21T01:48:33.148Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02697292"
    },
    {
      "nct_id": "NCT06597006",
      "title": "Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Familial Hypercholesterolemia - Homozygous"
      ],
      "interventions": [
        {
          "name": "Inclisiran",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "2 Years to 11 Years"
      },
      "enrollment_count": 9,
      "start_date": "2025-02-28",
      "completion_date": "2029-04-15",
      "has_results": false,
      "last_update_posted_date": "2026-07-24",
      "last_synced_at": "2026-11-21T01:48:33.148Z",
      "location_count": 4,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06597006"
    },
    {
      "nct_id": "NCT05354349",
      "title": "Bioavailability of SC Formulation and Japanese Ethnobridging Study for PRA023",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PRA023 IV Low Dose",
          "type": "DRUG"
        },
        {
          "name": "PRA023 SC",
          "type": "DRUG"
        },
        {
          "name": "Placebo IV",
          "type": "DRUG"
        },
        {
          "name": "Placebo SC",
          "type": "DRUG"
        },
        {
          "name": "PRA023 IV High Dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 49,
      "start_date": "2022-04-06",
      "completion_date": "2022-08-31",
      "has_results": false,
      "last_update_posted_date": "2024-01-16",
      "last_synced_at": "2026-11-21T01:48:33.148Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05354349"
    },
    {
      "nct_id": "NCT03100149",
      "title": "A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "RO7046015",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "40 Years to 80 Years"
      },
      "enrollment_count": 316,
      "start_date": "2017-06-27",
      "completion_date": "2031-12-01",
      "has_results": true,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-11-21T01:48:33.148Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 23 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03100149"
    },
    {
      "nct_id": "NCT05153148",
      "title": "A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriatic Arthritis"
      ],
      "interventions": [
        {
          "name": "NDI-034858",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 305,
      "start_date": "2022-01-06",
      "completion_date": "2023-06-02",
      "has_results": true,
      "last_update_posted_date": "2024-05-31",
      "last_synced_at": "2026-11-21T01:48:33.148Z",
      "location_count": 23,
      "location_summary": "Palm Desert, California • Upland, California • Hollywood, Florida + 19 more",
      "locations": [
        {
          "city": "Palm Desert",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Plantation",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05153148"
    },
    {
      "nct_id": "NCT07562087",
      "title": "A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lyme Disease"
      ],
      "interventions": [
        {
          "name": "TP-05 (lotilaner) Low Dose",
          "type": "DRUG"
        },
        {
          "name": "TP-05 (lotilaner) High Dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tarsus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 722,
      "start_date": "2026-03-09",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-11-21T01:48:33.148Z",
      "location_count": 19,
      "location_summary": "Pikesville, Maryland • Brookline, Massachusetts • Fall River, Massachusetts + 16 more",
      "locations": [
        {
          "city": "Pikesville",
          "state": "Maryland"
        },
        {
          "city": "Brookline",
          "state": "Massachusetts"
        },
        {
          "city": "Fall River",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Marlboro",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07562087"
    },
    {
      "nct_id": "NCT06699121",
      "title": "A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Sclerosing Cholangitis (PSC)"
      ],
      "interventions": [
        {
          "name": "LB-P8 low-dose",
          "type": "DRUG"
        },
        {
          "name": "LB-P8 high-dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "LISCure Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 87,
      "start_date": "2025-11",
      "completion_date": "2029-02",
      "has_results": false,
      "last_update_posted_date": "2025-10-24",
      "last_synced_at": "2026-11-21T01:48:33.148Z",
      "location_count": 7,
      "location_summary": "Sacramento, California • Aurora, Colorado • Iowa City, Iowa + 4 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06699121"
    },
    {
      "nct_id": "NCT07033026",
      "title": "An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "CRC (Colorectal Cancer)",
        "Cancer Cachexia"
      ],
      "interventions": [
        {
          "name": "NGM120 Q4W",
          "type": "DRUG"
        },
        {
          "name": "NGM120 Q8W",
          "type": "DRUG"
        },
        {
          "name": "Placebo given",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NGM Biopharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 136,
      "start_date": "2025-06-25",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-04-01",
      "last_synced_at": "2026-11-21T01:48:33.148Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Santa Rosa, California • Margate, Florida + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Margate",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07033026"
    },
    {
      "nct_id": "NCT00200850",
      "title": "Immunotherapy Administered Under the Tongue to Treat Dust Mite Allergy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "House Dust Mite SLIT",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High dose SLIT",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo SLIT",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 31,
      "start_date": "2006-01",
      "completion_date": "2008-10",
      "has_results": true,
      "last_update_posted_date": "2019-06-12",
      "last_synced_at": "2026-11-21T01:48:33.148Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00200850"
    },
    {
      "nct_id": "NCT01123655",
      "title": "Phase 1 Trial of Type II Collagen (CII) APL A12 in Rheumatoid Arthritis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "APLA12",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 22,
      "start_date": "2009-10",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2019-03-19",
      "last_synced_at": "2026-11-21T01:48:33.148Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01123655"
    }
  ]
}